Selinexor (Xpovio) — Nexpovio: Multiple Myeloma Treatment
Selinexor is a first-in-class "Nuclear Export Inhibitor" that acts like a jailkeeper for cancer cells. It targets a protein called XPO1, which normally transports tumor-suppressor proteins (the body's natural cancer fighters) out of the cell nucleus.
The Mechanism: Selinexor (brand name Xpovio) blocks XPO1, locking these tumor suppressors inside the nucleus. Once trapped, they activate the cancer cell's self-destruct sequence. This unique mechanism offers new hope for patients with Multiple Myeloma and Lymphoma who have exhausted other treatment options.
It is an oral medication taken weekly, typically in combination with dexamethasone and other agents like bortezomib.
Indications
- Multiple Myeloma: For adult patients with relapsed or refractory multiple myeloma who have received prior therapies (including proteasome inhibitors and immunomodulatory agents).
- Diffuse Large B-Cell Lymphoma (DLBCL): For adults with relapsed or refractory disease after at least two lines of systemic therapy.
Dosage and administration
Selinexor has a specific weekly dosing schedule, different from daily meds.
- Weekly Schedule: Typically taken once a week (e.g., every Tuesday) on a fixed schedule. Dosage (e.g., 80 mg or 100 mg) is determined by your oncologist.
- Administration: Swallow tablets whole with water. Can be taken with or without food.
- Crucial — Nausea Prevention: Because nausea is a very common side effect, your doctor will prescribe prophylactic anti-nausea medications (antiemetics). You must take these BEFORE your dose of Selinexor to prevent symptoms.
- Hypersensitivity to Selinexor.
- Pregnancy and breastfeeding (can cause fetal harm).
- Severe uncontrolled infections.
Selinexor is potent, and managing side effects is key to successful treatment.
- Gastrointestinal (Very Common): Nausea, vomiting, diarrhea, loss of appetite, and weight loss. Hydration and caloric intake are critical.
- Blood: Thrombocytopenia (low platelets — bruising risk), anemia, neutropenia.
- Physical: Significant fatigue and weakness are often reported.
- Electrolytes: Hyponatremia (low sodium levels), which requires regular blood monitoring.
